EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseOpen Access · CC BY 4.0

Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials

Audrey Godin, Elizabeth B Brickley, Ruth I Connor, Wendy F Wieland-Alter, Margaret E Ackerman, Joshua A Weiner, John Modlin, Minetaro Arita, Ananda S Bandyopadhyay, Chris Gast, Xavier Sáez-Llorens, Ricardo W Rüttimann und 3 weitere

The Lancet Microbe · 2025

DOI: 10.1016/j.lanmic.2024.101028 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Lancet Microbe, 2025. Verfasst von Audrey Godin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Health Equity Action Lab, Department of Infectious Disease Epidemiology and International Health, London School of Hygiene & Tropical Medicine, Londo…. Hauptthemen laut MEDLINE: Immunity, Mucosal, Intestinal Mucosa, Poliomyelitis, Poliovirus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Bill & Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A novel oral polio vaccine type 2 (nOPV2), which is more genetically stable (ie, lower risks of reverting to neurovirulence) than the Sabin monovalent OPV2 (mOPV2), has been deployed to interrupt circulating vaccine-derived poliovirus type 2 (PV2) outbreaks. This study compares intestinal mucosal immune responses induced by nOPV2 and mOPV2. METHODS: In this analysis, we evaluated intestinal mucosal immune responses in healthy participants of different ages (ie, infants aged 18-22 weeks, children aged 1-4 years, and adults aged 18-50 years) and vaccine backgrounds (ie, OPV2-experienced vs OPV2-naive). Participants were selected from two phase 2 trials of nOPV2, conducted in 2018-19 (infants and children, NCT03554798 [Panama]; adults, EudraCT 2018-001684-22-NCT04544787 [Belgium]), and two phase 4 historical control trials of mOPV2, conducted in 2015-16 (infants and children, NCT02521974 [Panama]; adults, EudraCT 2015-003325-33 [Belgium]). We measured PV2-specific neutralising activity and IgA concentrations in stools collected before and 14 days after vaccination. FINDINGS: We compared data from 160 participants (ie, 47 infants, 47 children, and 66 adults) in the nOPV2 trials to 188 participants (ie, 42 infants, 46 children, and 100 adults) in the mOPV2 trials. Within each age group, one dose of nOPV2 or mOPV2 induced similar intestinal PV2-specific neutralisation and IgA responses on day 14. Responses diminished with age: among the OPV2-naive participants who received nOPV2, 27 (82%) of 33 infants, 17 (61%) of 28 children, and four (25%) of 16 adults had detectable PV2-specific neutralisation on day 14. Despite having similar median log10 IgA responses (1·4 [IQR 1·0-2·2] vs 1·4 [1·1-1·7], p=0·34) and median log2 neutralisation titres (1 [IQR 1-1] vs 1 [1-1·5], p=0·89) on day 14, a smaller percentage of OPV2-experienced adults shed vaccine virus than OPV2-naive adults upon nOPV2 challenge (20% vs 82%, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunity, MucosalIntestinal MucosaPoliomyelitisPoliovirusPoliovirus Vaccine, OralAdolescentAdultChild, PreschoolFemaleHumansInfantMaleMiddle AgedYoung AdultAntibodies, NeutralizingAntibodies, ViralImmunoglobulin AClinical Trials, Phase II as TopicClinical Trials, Phase IV as TopicRandomized Controlled Trials as Topic

Substanzen

Antibodies, NeutralizingAntibodies, ViralImmunoglobulin APoliovirus Vaccine, Oral

Autor:innen und Institutionen

  • Health Equity Action Lab, Department of Infectious Disease Epidemiology and International Health, London School of Hygiene & Tropical Medicine, London, UK.
  • Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth Health, Lebanon, NH, USA.
  • Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.
  • Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
  • Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • PATH Center for Vaccine Innovation and Access, Seattle, WA, USA.

Förderung

  • Japan Agency for Medical Research and Development
  • Bill & Melinda Gates Foundation

Zitieren

APA

Godin, A., Brickley, E. B., Connor, R. I., Wieland-Alter, W. F., Ackerman, M. E., Weiner, J. A., Modlin, J., Arita, M., Bandyopadhyay, A. S., Gast, C., Sáez-Llorens, X., Rüttimann, R. W., Van Damme, P., De Coster, I., & Wright, P. F. (2025). Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2024.101028

Vancouver

Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Ackerman ME, Weiner JA, et al. Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials. The Lancet Microbe. 2025. doi:10.1016/j.lanmic.2024.101028

BibTeX
@article{Godin2025,
  author = {Godin, Audrey and Brickley, Elizabeth B and Connor, Ruth I and Wieland-Alter, Wendy F and Ackerman, Margaret E and Weiner, Joshua A and Modlin, John and Arita, Minetaro and Bandyopadhyay, Ananda S and Gast, Chris and Sáez-Llorens, Xavier and Rüttimann, Ricardo W and Van Damme, Pierre and De Coster, Ilse and Wright, Peter F},
  title = {Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials},
  journal = {The Lancet Microbe},
  year = {2025},
  doi = {10.1016/j.lanmic.2024.101028}
}
Kostenlos starten →